KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Accounts Payables (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Accounts Payables data on record, last reported at $461.7 million in Q4 2025.

  • For Q4 2025, Accounts Payables rose 11.79% year-over-year to $461.7 million; the TTM value through Dec 2025 reached $461.7 million, up 11.79%, while the annual FY2025 figure was $461.7 million, 11.79% up from the prior year.
  • Accounts Payables reached $461.7 million in Q4 2025 per VRTX's latest filing, up from $420.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $461.7 million in Q4 2025 and bottomed at $126.9 million in Q3 2022.
  • Average Accounts Payables over 5 years is $303.3 million, with a median of $339.6 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: surged 196.22% in 2023, then decreased 9.67% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $195.0 million in 2021, then skyrocketed by 55.85% to $303.9 million in 2022, then grew by 20.07% to $364.9 million in 2023, then increased by 13.18% to $413.0 million in 2024, then increased by 11.79% to $461.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $461.7 million in Q4 2025, $420.3 million in Q3 2025, and $442.3 million in Q2 2025.